Reliv International Reports Fourth-Quarter And Full-Year Financial Results For 2012

CHESTERFIELD, Mo., March 6, 2013 (GLOBE NEWSWIRE) -- Reliv International, Inc. (Nasdaq:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth quarter and full year of 2012.

Fourth-Quarter Results

Reliv reported net sales of $16.91 million for the fourth quarter of 2012, compared with sales of $16.89 million for the fourth quarter of 2011, an increase of 0.1 percent. U.S. sales declined by 3.2 percent for the quarter compared with the same quarter in 2011. International sales for the quarter increased 13.1 percent, led by significant growth in Europe, which reported an increase of 49.5 percent.

Reliv reported net income of $437,000, or $0.03 per diluted share, for the fourth quarter of 2012 compared with net income of $320,000, or $0.03 per diluted share, for the fourth quarter of 2011. Income from operations for the fourth quarter of 2012 was $611,000 compared with $471,000 in the same quarter of 2011.

Full-Year Results

Reliv reported net sales of $68.71 million for 2012 compared with net sales of $73.88 million in 2011. U.S. net sales decreased from $60.88 million to $53.80 million. Net sales in Reliv's foreign markets for 2012 increased 14.7 percent compared with net sales for 2011. Net sales were particularly strong in Europe, where net sales increased by $2.73 million, or 72.7 percent. Growth in the European market in 2012 was driven by strong increases in new distributor enrollments and new Master Affiliate qualifications, along with the launch of Reliv NOW ® with LunaRich ® in October 2012.

Net income for 2012 was $1.36 million compared with $1.05 million in 2011. Diluted earnings per share were $0.11 in 2012 compared with $0.08 in 2011.

"The net sales increase in the fourth quarter of 2012 compared with the fourth quarter of 2011 marks the first quarterly year-over-year net sales increase in more than five years at Reliv," said Robert L. Montgomery, chairman and chief executive officer of Reliv. "We believe that with continuing growth in Europe and initiatives underway worldwide it is the first of many to come."

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Raising The Consumer Goods Sector Higher

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Driving The Drugs Industry Higher

3 Health Care Stocks Pushing The Sector Higher